Inclusion Criteria:  Male or female, age 21-70 (inclusive) with at least 3 years of life expectancy; Subject plans to undergo a one-level Open or Mini-Open TLIF procedure (stabilized with pedicle screws) independent of this research protocol; Subject is to be treated with on-label use of an FDA-cleared TLIF cage and pedicle screw system independent of this research protocol;  The subject has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar spine at a single level from L1/L2 to L5/S1 confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 1 (<25% translation) spondylolisthesis. Symptomatic lumbar degeneration that may be associated with a co-morbid condition such as:  Herniated nucleus pulposus; Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule; Facet joint degeneration/osteophyte formation; Spondylosis (defined by the presence of osteophytes); Disc degeneration and/or annular degeneration; and/or Lumbar stenosis defined by spinal cord or nerve root compression; Exhausted conservative treatment (e.g. bed rest, physical therapy, medications, transcutaneous electrical nerve stimulation (TENS), manipulation, and/or spinal injections) for at least 3 months or has a neurologic emergency; Preoperative Oswestry Disability Index score > 40/100 at baseline; Preoperative total leg pain and/or total back pain score > 40/100 on the Visual Analog Scale at baseline; Surgical candidate for a posterior approach to the lumbar spine; Psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms; and Signed informed consent.  Exclusion Criteria:  More than one vertebral level requiring treatment; Previous instrumented surgery (i.e.: anterior disc replacement, spinal fusion, interspinous device, etc.) at the index lumbar level or an adjacent level; Degenerative or lytic spondylolisthesis greater than Grade 1 (<25% translation); Rotatory scoliosis at the level to be treated; Congenital bony and/or spinal cord abnormalities at the level to be treated; Subcaudal defect, disrupting the integrity of the pedicle; Clinically compromised vertebral bodies at the involved level due to current or past trauma, e.g., by the radiographic appearance of the fracture callus, malunion or nonunion; Disrupted anterior longitudinal ligament at the index level; Overlying thoracolumbar kyphosis within one level (includes target and adjacent level) of the level to be treated; Back pain of unknown etiology without leg pain;  Severe spondylosis at the level to be treated as characterized by any of the following:  Autofusion (solid arthrodesis) determined radiographically (CT); Totally collapsed disc, or; Vertebral body that cannot be mobilized; Known allergy to cobalt, chromium, molybdenum, nickel, polyethylene, titanium, or vitamin E; Unable to undergo an MRI scan, CT scan or other radiograph assessments; Osteopenia: All patients will complete SCORES/MORES to screen if a dual energy x-ray absorptiometry (DEXA) scan is indicated. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score ≤ -1. An existing DEXA is allowed if completed within 6 months of subject screening; Has history of any endocrine or metabolic disorder known to affect osteogenesis (e.g.: Paget's disease, renal osteodystrophy, Ehler-Danlos syndrome, or osteogenesis imperfecta); Insulin-dependent diabetes mellitus; Lactating, pregnant or interested in becoming pregnant in the next 3 years; Active infection - systemic or local; Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study; Body Mass Index > 40; Recurrent history of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolic disease; Systemic disease including Lupus disease, Reiter's disease, Rheumatoid disease, AIDS, HIV, hepatitis or autoimmune disease that requires immunosuppressive therapy, including biologics, for systemic inflammation; Spinal tumor; Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years; Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis; Has chronic or acute renal and/or hepatic impairment and/or failure or prior history of renal and/or hepatic parenchymal disease; Has a Waddell Signs of Inorganic Behavior score of 3 or greater; In the opinion of the investigator, the subject has a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device; Current or recent history of chemical/alcohol abuse or dependency using standard medical definition of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) code; Currently smoking or using tobacco products, including e-cigarette products (e.g., vaping); Currently pursuing or in active spinal litigation for medical negligence, or trauma, or workers compensation; Is a prisoner, incarcerated, or has been coerced to participate in the study that could impact the validity of results; Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 24 months following enrollment into the study.